Klaviyo to Present at the 44th Annual Canaccord Growth Conference
Klaviyo to Present at the 44th Annual Canaccord Growth Conference
Klaviyo (NYSE: KVYO), the company that powers smarter digital relationships, today announced that Andrew Bialecki, Co-Founder and Chief Executive Officer, will participate in a fireside chat at the 44th Annual Canaccord Growth Conference on Wednesday, August 14, 2024 at 11:00 a.m. ET (8:00 a.m. PT).
A live webcast and replay will be available on the Company’s investor relations website at https://investors.klaviyo.com/.
About Klaviyo
Klaviyo (CLAY-vee-oh) powers smarter digital relationships, making it easy for businesses to capture, store, analyze, and predictively use their own data to drive measurable, high-value outcomes. Klaviyo’s modern and intuitive SaaS platform enables business users of any skill level to harness their first-party data from more than 350 integrations to send the right message at the right time across email, SMS, and push notifications. Innovative businesses like Mattel, TaylorMade, Liquid Death, Stanley 1913, and more than 151,000 other paying customers leverage Klaviyo to acquire, engage, and retain customers—and grow on their own terms.
Tag: IR
Investor Relations:
Andrew Zilli
ir@klaviyo.com
Press:
Lacey Berrien
press@klaviyo.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808777073/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks